[What's new in 2009 about urothelial tumors? Live from EAU, AUA and ASCO, ASCO-GU].
During the EAU and AUA congress in 2009, major work about the urothelial carcinoma was interested in the classification T1a / b and its therapeutic consequences, the last results of BCG therapy and photodynamic diagnosis. At ASCO congress, the main studies presented focused on the systemic treatment, in adjuvant situation, in first line treatment of metastatic bladder cancer, particularly with the addition of anti-angiogenic to chemotherapy, and in conservative treatment in association with radiotherapy.
Amsellem-Ouazana
D
D
Comité de cancérologie de l'AFU - Sous Comité Vessie CCAFU.
Theodore
C
C
Irani
J
J
Bernardini
S
S
Bonnal
J-L
JL
Chauvet
B
B
Colombel
M
M
Davin
J-L
JL
Laurent
G
G
Lebret
T
T
Maidenberg
M
M
Mazerolles
C
C
Pfister
C
C
Roupret
M
M
Roy
C
C
Rozet
F
F
Saint
F
F
Soulié
M
M
Guillotreau
J
J
D003226:Congresses as Topic; D006801:Humans; D001749:Urinary Bladder Neoplasms / Q000628:therapy*